The therapeutic landscape in ALK-positive NSCLC is rapidly developed in recent years, and lung cancers that harbor chromosomal rearrangements of ALK are highly sensitive to small-molecule tyrosine kinase inhibitors targeting at ALK23. This evidence concerns the gene ALK and lung carcinoma.